Aptorum Group Limited

NasdaqCM:APM

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United Kingdom

Market Cap

USD 7.07 M

Share Price

USD 0.99

Avg Daily Volume

79,879

Change (1 day)

-1.00%

Change (1 year)

-79.25%

Change (YTD)

32.80%

Aptorum Group Limited Revenue for the year ending December 31, 2024

Aptorum Group Limited Revenue is NA for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Aptorum Group Limited Revenue for the year ending December 31, 2023 was USD 431.38 K, a -66.71% change year over year.
Aptorum Group Limited Revenue for the year ending December 31, 2022 was USD 1.30 M, a -15.95% change year over year.
Aptorum Group Limited Revenue for the year ending December 31, 2021 was USD 1.54 M, a 69.17% change year over year.
Aptorum Group Limited Revenue for the year ending December 31, 2020 was USD 911.51 K, a 70.32% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqCM: APM

Aptorum Group Limited

CEO	Mr. Chung Yuen Huen
IPO Date	Dec. 18, 2018
Location	United Kingdom
Headquarters	17 Hanover Square
Employees	1
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.